Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CTX112 |
Synonyms | |
Therapy Description |
CTX112 are allogeneic T-lymphocytes engineered to harbor modifications of Regnase-1 and TGFBR2 and express a chimeric antigen receptor (CAR) targeting CD19, which potentially lead to enhanced antitumor immune response and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): ND02). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTX112 | CTX 112|CTX-112 | CTX112 are allogeneic T-lymphocytes engineered to harbor modifications of Regnase-1 and TGFBR2 and express a chimeric antigen receptor (CAR) targeting CD19, which potentially lead to enhanced antitumor immune response and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): ND02). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05643742 | Phase Ib/II | CTX112 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | Recruiting | USA | AUS | 0 |